Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Vecabrutinib is 1 of 3 investigational BTK inhibitors that is being evaluated in patients with B-cell malignancies. Vecabrutinib is unique from the currently approved BTK inhibitors in that it is reversible and noncovalent, explains Allan. When patients progress on irreversible, covalent BTK inhibitors, they typically acquire a resistance mutation; this is not the case with the reversible BTK inhibitors, says Allan.

The drug is currently under evaluation in a phase Ib/II trial. To be eligible for enrollment, patients had to have received ≥2 prior lines of therapy and progressed on a covalent BTK inhibitor, adds Allan. Several histologic subtypes have accrued to the trial, including those with chronic lymphocytic leukemia, Waldenström Macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. To date, 29 patients have enrolled on the trial, results regarding these patients were presented at the 2019 ASH Annual Meeting, concludes Allan.

Related Videos
Wenjun (Tia) Li, on Reducing Swelling in Mouse Models of Rheumatoid Arthritis With Gene Therapy
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
© 2023 MJH Life Sciences

All rights reserved.